Möller H J, Volz H P
Department of Psychiatry, University of Bonn, FRG.
J Affect Disord. 1992 Nov;26(3):163-72. doi: 10.1016/0165-0327(92)90012-u.
In an 8-week controlled double-blind clinical trial with a total of 216 patients Brofaromine was found to be superior to Imipramine with regard to efficacy (Hamilton Depression Scale, von Zerssen self-rating scale, global evaluation) and tolerability (adverse experiences, global evaluation). Mean daily dosages were 93.1 mg/day in the Brofaromine group and 92 mg/day in the Imipramine Group. No tyramine reduced diet had to be observed. Long-term efficacy and tolerability also proved to be good in an open follow-up in the Brofaromine group.
在一项为期8周、共有216名患者参与的对照双盲临床试验中，发现溴法罗明在疗效（汉密尔顿抑郁量表、冯·泽尔森自评量表、整体评估）和耐受性（不良事件、整体评估）方面优于丙咪嗪。溴法罗明组的平均日剂量为93.1毫克/天，丙咪嗪组为92毫克/天。无需观察酪胺减少饮食情况。在溴法罗明组的开放随访中，长期疗效和耐受性也被证明良好。
